Speaker illustration

Mr Maxim Grymonprez

Ghent University, Ghent (Belgium)

Member of:

European Society of Cardiology
European Heart Rythm Association

Optimal adherence threshold to non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation to reduce the risk of thromboembolism and death

Event: ESC Congress 2023

Topic: Anticoagulants

Session: Oral anticoagulation in patients with atrial fibrillation

Thumbnail

The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study

Event: EHRA 2023

Topic: Oral Anticoagulation

Session: Atrial Fibrillation - Round 1 - Stroke - OAC

Thumbnail

Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study

Event: ESC Congress 2022

Topic: Anticoagulants

Session: Anticoagulant therapy: real world use and clinical challenges

Thumbnail

Impact of P-glycoprotein and/or CYP3A4-interacting drugs on the risk-benefit profile of NOACs in patients with atrial fibrillation: a meta-analysis

Event: EHRA 2022

Topic: Oral Anticoagulation

Session: Moderated ePosters - How to optimise stroke prevention in atrial fibrillation

Thumbnail

Non-vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in (morbidly) obese or low body weight patients with atrial fibrillation: a meta-analysis

Event: EHRA 2021

Topic: Oral Anticoagulation

Session: ePoster session

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb